Eucardia

Eucardia S.r.l. is a medical technology company that has developed the Heart Damper, a device for treating systolic heart failure. The company was founded in 2013, with operations starting in 2014, and is headquartered in Milan, Italy. The concept for the Heart Damper originated from Professor Roberto Parravicini, a cardiac surgeon with extensive experience in Italy and the United States, who saw the need for a better solution for heart failure patients. He co-founded the company with his daughter, Francesca Parravicini, who has a background in publishing and manages investor relations and corporate communications for Eucardia. The management team also includes CEO Marco Bottaro.

The company's core product, the Heart Damper, is a minimally invasive implantable cardiac device designed to be fitted into the left ventricle via a transapical surgical procedure. It aims to improve cardiac function by leveraging the heart's residual contractility, thereby increasing the ejection fraction without requiring an external power source. This approach is intended to offer a simpler, more cost-effective, and less invasive treatment compared to existing options like heart transplants or other complex devices, which are often not suitable for all patients due to age or donor availability. The device is protected by patents granted in Europe, the US, and other countries.

Eucardia operates in the MedTech sector, specifically targeting the growing market for heart failure, a condition affecting millions globally and representing a significant burden on healthcare systems. The company's business model is B2B, focused on validating the Heart Damper technology through pre-clinical and clinical trials to eventually sign licensing agreements with larger MedTech corporations for commercialization and distribution. Eucardia has engaged in pre-clinical validation, including in-vivo animal studies and using cardiac biosimulator platforms to test and refine the device's design and performance. The company has secured funding through various channels, including winning the Gaetano Marzotto Prize and completing a capital increase to advance toward human trials.

Keywords: Heart Damper, systolic heart failure, implantable cardiac device, MedTech, cardiac surgery, left ventricle, minimally invasive, heart failure therapy, medical device, cardiovascular, B2B licensing, pre-clinical trials, cardiac efficiency, transapical procedure, Roberto Parravicini, Francesca Parravicini, Marco Bottaro